Clinical trials: Mononegavirales Infections
Measles, Varicella
Immunogenicity & Safety Study of GSK Biologicals' Combined Measles-mumps-rubella-varicella Vaccine 208136
This Phase 3b study is being conducted for the purpose of registration of the GSK208136 vaccine in Korea.
- Conditions
- Measles, Varicella, Mumps, Rubella
- Trial name
- NCT00751348
- Testing
- PriorixTM, VarilrixTM, Priorix-Tetra®
- Where
- 13 sites in South Korea
- Volunteers
- 475 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Bronchiolitis, Bronchiolitis, Viral
Nasal and Bronchial Absorption Sampling in RSV Bronchiolitis
This study will compare the novel methods of NS and BS with the standard technique of nasophayngeal aspiration (NPA) and routine ETT suction.
- Conditions
- Bronchiolitis, Bronchiolitis, Viral, RSV Infection, Respiratory Failure
- Trial name
- RSV-SAM (NCT03062917)
- Testing
- Nasal and Bronchial Sampling
- Where
- United Kingdom
- Volunteers
- 152 people, healthy volunteers welcome
- Sponsor
- Imperial College Healthcare NHS Trust
Respiratory Syncytial Virus Infection
Study on a Live-attenuated Respiratory Syncytial Virus Vaccine for Assessment of Safety, Transmissibility, and Genetic Stability of the Vaccine Virus Among Close Contacts in Infants and Toddlers 6 to < 24 Months of Age in Puerto Rico (USA)
The primary purpose of the study is to assess the shedding, transmission, and genetic stability of the live-attenuated RSVt vaccine after each intranasal vaccination (56 days apart) in infants and toddlers 6 to < 24 months of age.
- Trial name
- NCT05687279
- Testing
- RSVt Vaccine, Control Group
- Where
- 6 sites in United States, Puerto Rico
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Marburg Virus Disease
A Study to Evaluate the Single Dose Safety, Tolerability and Pharmacokinetics of IV BCX4430
This is a placebo-controlled, randomized, double-blind study to evaluate the pharmacokinetics of galidesivir following administration of single doses by IV infusion
- Trial name
- NCT03800173
- Testing
- galidesivir
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- BioCryst Pharmaceuticals
Measles, Mumps
Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP)(V221-027)
This study will compare the safety, tolerability, and immunogenicity of measles, mumps, rubella, and varicella (MMRV) vaccine made with an alternative manufacturing process with those of the 2006 process
- Conditions
- Measles, Mumps, Rubella, Varicella
- Trial name
- NCT01536405
- Testing
- MMRV (AMP), MMRV (2006 process)
- Volunteers
- 1,412 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Respiratory Syncytial Virus Infections
Efficacy Study of GSK's Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above
This study will evaluate the efficacy of the RSVPreF3 OA investigational vaccine in preventing Lower Respiratory Tract Disease (LRTD) caused by RSV in adults ≥60 years of age following a single dose of the RSVPreF3 OA vaccine and…
- Trial name
- NCT04886596
- Testing
- RSVPreF3 OA vaccine
- Where
- 277 sites in United States, Australia and 15 more
- Volunteers
- 26,675 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
RSV Infection
The Impact of Age on Adaptive Immunity in Adults Infected With Respiratory Syncytial Virus
This study will for the first time systematically investigate the immune responses in an elderly cohort challenged with a well-defined RSV inoculum.
- Trial name
- INFLAMMAGE (NCT03728413)
- Testing
- RSV A Memphis 37
- Where
- United Kingdom
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Respiratory Syncytial Virus Infection
Efficacy, Pharmacokinetics, and Safety of Presatovir in Hospitalized Adults With Respiratory Syncytial Virus (RSV) Infection
The primary objective of this study is to evaluate the effects of presatovir on respiratory syncytial virus (RSV) viral load in RSV-positive adults who have been hospitalized with acute respiratory infectious symptoms.
- Trial name
- NCT02135614
- Testing
- Presatovir
- Where
- 43 sites in United States, Australia and 9 more
- Volunteers
- 189 people
- Sponsor
- Gilead Sciences
Rabies
Comparison of SYN023 to Human Rabies Immune Globulin in Post Exposure Prophylaxis of Rabies
This is a Phase 2b, double blinded, randomized study of SYN023 compared to HyperRab® (a licensed Rabies immune globulin from human sources, HRIG) for the prevention of rabies as part of post-exposure prophylaxis (PEP).
- Trial name
- ARPEP (NCT03961555)
- Testing
- SYN023, HRIG (HyperRab), Rabies vaccine
- Where
- 14 sites in United States, Philippines
- Volunteers
- 448 people
- Sponsor
- Synermore Biologics Co., Ltd.
Respiratory Syncytial Virus Infections
A Study to Learn About the Amount of the Study Medicine (Sisunatovir) in Blood and Its Safety in Infants and Children With Pneumonia Caused by RSV
The purpose of the study is to learn about the safety and amount of sisunatovir in the blood of infants and children up to age 60 months.
- Trial name
- NCT06102174
- Testing
- Active
- Where
- 9 sites in United States, Japan and 1 more
- Volunteers
- 10 people
- Sponsor
- Pfizer
Respiratory Syncytial Virus Infection
Surveillance of Synagis in Korean Pediatric Patients
Approximately 600 pediatric patients prescribed palivizumab (Synagis) prophylaxis in usual practice according to the approved Korean product label will be registered into this observational study.
- Trial name
- NCT01537198
- Volunteers
- 618 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Respiratory Syncytial Virus Infection
Study of an Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers
The primary objectives of the study were: To assess the safety profile of each dose of the study product after each and any administration in all infants and toddlers regardless of baseline serostatus.
- Trial name
- VAD00001 (NCT04491877)
- Testing
- RSV vaccine formulation 1, RSV vaccine formulation 2
- Where
- 29 sites in United States, Chile and 1 more
- Volunteers
- 259 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Respiratory Syncytial Virus Infections
A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 50-59 Years of Age, Including Adults at Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease, Compared to Older Adults 60 Years of Age and Above
The aim of this study is to demonstrate the non-inferiority (NI) of the immune response and evaluate safety of RSVPreF3 older adults (OA) investigational vaccine in adults 50-59 years of age (YOA), including those who are at…
- Trial name
- NCT05590403
- Testing
- RSVPreF3 OA investigational vaccine
- Volunteers
- 1,544 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Respiratory Syncytial Virus Infections
Study of RSVpreF Vaccination and RSV Challenge in Healthy Adults
In this randomised, placebo-controlled, double-blind Phase 2a study, healthy male and female participants 18-50 years of age will be given an investigational RSV vaccine (RSVpreF) and challenged with RSV one month later.
- Trial name
- NCT04785612
- Testing
- RSVPreF
- Where
- United Kingdom
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Hvivo
Bone Marrow Transplant Infection, Infection in Marrow Transplant Recipients
Respiratory Syncytial Virus - RSV Protocol
The goal of this clinical research study is to learn if ribavirin can help to control RSV in patients with immune systems that have been weakened by a stem cell transplant.
- Conditions
- Bone Marrow Transplant Infection, Infection in Marrow Transplant Recipients, Respiratory Syncytial Virus Infections, Respiratory Syncytial Virus Pneumonia
- Trial name
- NCT01502072
- Testing
- Ribavirin
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- M.D. Anderson Cancer Center
RSV Infection
A Phase 2a Study to Evaluate EDP-938 in the Virus Challenge Model
A randomised, Phase 2a, double-blind, placebo-controlled study to evaluate the safety, pharmacokinetics and antiviral activity of multiple doses of orally administered EDP-938 in healthy subjects infected with RSV-A Memphis 37b.
- Trial name
- NCT03691623
- Testing
- EDP-938 Dose 1, EDP-938 Dose 2, EDP-938 Dose 3
- Where
- United Kingdom
- Volunteers
- 179 people, healthy volunteers welcome
- Sponsor
- Enanta Pharmaceuticals, Inc
Severe Respiratory Syncytial Virus Infection
Retrospective Palivizumab Study in Children With Hemodynamically Significant Congenital Heart Disease
Retrospective medical record review study of specific adverse events in children with congenital heart disease who received palivizumab for prophylaxis of serious respiratory syncytial virus infection and control subjects that…
- Trial name
- NCT01075178
- Where
- 37 sites in Austria, Belgium and 8 more
- Volunteers
- 2,036 people
- Sponsor
- Abbott
Respiratory Syncytial Virus Infections
A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone or Co-administered With an Adjuvanted Vaccine Against Influenza in Adults Aged 65 Years and Above
The aim of this study is to assess the immunogenicity, safety and reactogenicity of the RSV PreFusion protein 3 older adult (RSVPreF3 OA) investigational vaccine when co-administered with an adjuvanted quadrivalent influenza (FLU…
- Trial name
- NCT05568797
- Testing
- RSVPreF3 OA vaccine, FLU vaccine
- Where
- 37 sites in Belgium, Finland and 3 more
- Volunteers
- 1,045 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Rubella, Mumps
Immunogenicity of GSKs' MMR Vaccine (209762) vs. M-M-R® II, When Given With Routine Vaccines at 12-15 Months of Age
The purpose of this study is to compare two measles, mumps and rubella conjugate vaccines (manufactured by GSK and Merck and Company ) in terms of the immune response elicited and safety with a six month follow-up after first…
- Conditions
- Rubella, Mumps, Measles, Measles-Mumps-Rubella Vaccine
- Trial name
- NCT00861744
- Testing
- GSK Biological's investigational vaccine 209762, M-M-R® II (Merck and Co), Varivax®
- Where
- 48 sites in United States, Puerto Rico
- Volunteers
- 1,259 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Respiratory Syncytial Virus Infections
A Phase III Study to Assess the Lot-to-lot Consistency of GSK's Investigational RSV Maternal Vaccine and the Immune Response and Safety of RSV Maternal Vaccine When Given Alone or Co-administered With GSK's Influenza D-QIV Vaccine in Healthy Non-pregnant Women.
The purpose of this study is to evaluate the clinical lot-to-lot consistency of the respiratory syncytial virus (RSV) maternal (RSV MAT) vaccine administered to healthy non-pregnant women 18-49 years of age (YOA).
- Trial name
- NCT05045144
- Testing
- RSVPreF3(120 μg), Flu Quadrivalent influenza vaccine (15 μg HA)
- Where
- 36 sites in United States, Canada and 3 more
- Volunteers
- 1,586 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline